En Es
Categories

Industry News

Ortho Clinical Diagnostics and EKF Diagnostics Collaborate for Assay

By Labmedica International staff writers
17 Oct 2017

Image: The VITROS 5600 integrated system (Photo courtesy of Ortho Clinical Diagnostics).Ortho Clinical Diagnostics (Raritan, NJ, USA) and EKF Diagnostics (Wales, UK) have entered into an agreement that allows Ortho customers to access the Beta-Hydroxybutyrate (BHB) assay, an important marker used in conjunction with clinical findings and other lab tests for the diagnosis and management of ketoacidosis and its main causative factor, diabetic ketoacidosis (DKA). The fully automated assay is now available for use on Ortho's VITROS 4600 chemistry system and the VITROS 5600 integrated system.

Ortho’s in vitro diagnostics products and services for the clinical laboratory and immunohematology communities include blood typing products, sophisticated testing technologies, automation, information management and interpretation tools. EKF Diagnostics, through its wholly owned subsidiary, Stanbio Laboratory, manufactures a comprehensive range of clinical chemistry reagents, rapid tests and benchtop chemistry analyzers. EKF Diagnostics' enzymatic BHB assay is used primarily for determining both the presence and degree of ketosis in suspected DKA cases and produces a quantitative value that is specific to the BHB “ketone body.”

Ortho and EKF Diagnostics are collaborating to provide the BHB assay as a validated MicroTip Partnership Assay (MPA) application in the US and Canada. This MPA utilizes the user defined assay feature, which provides the capability to program assay parameters as defined in the EKF- Stanbio Assay Application Sheet. The BHB LiquiColor assay has been CLIA classified by the U.S. Food and Drug Administration as a MODERATE complexity assay on the VITROS 4600 Chemistry System and VITROS 5600 Integrated System.

"Ortho is committed to delivering a broad menu of assays to our customers in the clinical lab, whether through in-house development or collaborations like the one with EKF," said Ortho's Chief Operating Officer Robert Yates.

"Diabetic ketoacidosis is a serious condition, and our collaboration with Ortho Clinical Diagnostics will help to deliver the important BHB assay to their existing customers," said EKF's Diagnostics Head of Sales, Gilbert Mejia.



E-mail Print
FaceBook Twitter Google+ Linked in

ORTHO CLINICAL DIAGNOSTICS

Ortho Clinical Diagnostics is a global provider of in vitro diagnostics, including testing platforms and clinical assay tests to monitor disease progression across multiple disease categories such as infectious diseases, cardiology and endocrinology. It also offers laboratory systems and blood typing products in immunohematology to hospitals, hospital networks, blood banks, and labs around the world.
More info

More articles about ORTHO CLINICAL DIAGNOSTICS

20 May 2019
Ortho Clinical Diagnostics Presents Cardiac Advances at EuroMedLab 2019
Ortho Clinical Diagnostics sponsored an educational workshop on high-sensitivity troponin assays and presented five scientific posters at EuroMedLab 2019, the 23rd IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine, which took place from May 19-23, 2019, at the CCIB - Centre Convencions Internacional in Barcelona.
Read More

Additional news

21 Apr 2021
FDA Clears First-Ever AI Mammography Triage Software that Supports both 3D and 2D Mammography
The US Food and Drug Administration has cleared the first-ever artificial intelligence (AI) mammography triage software that supports both 3D and 2D mammography.
Read More
20 Apr 2021
Global Digital PCR and Real-Time PCR Market Growth Driven by Increasing Cases of Infectious Diseases
Increasing cases of infectious diseases, rising geriatric population and growing number of genetic disorders will propel the growth of the global digital PCR and real-time PCR market over the next decade. Additionally, PCR advances, fulfillment of the human genome project, and expanding R&D will increase the utilization of biomarker profiling for sickness diagnostics, thus further driving market growth.
Read More
19 Apr 2021
Siemens Completes Acquisition of Varian to Create Integrated Portfolio of Imaging, Laboratory Diagnostics, AI and Cancer Treatment
Siemens Healthineers (Erlangen, Germany) has successfully completed the acquisition of Varian Medical Systems, Inc. (Palo Alto, CA, USA), thus strengthening its position as a holistic partner in healthcare.
Read More
16 Apr 2021
Eppendorf Introduces Multipurpose Centrifuge 5910 Ri to Accelerate Results
Eppendorf AG (Hamburg, Germany) has introduced a new centrifuge designed to increase efficiency in the laboratory, Centrifuge 5910 Ri, a successor to the company’s popular Centrifuge 5910 R.
Read More
16 Apr 2021
Artificial Intelligence (AI) in Medical Diagnostics Market to Reach USD 3.86 Billion by 2025
The global Artificial Intelligence (AI) in Medical Diagnostics Market is projected to grow at a CAGR of 50.2% from USD 0.5 billion in 2020 to USD 3.86 billion by 2025, driven primarily by government initiatives to increase the adoption of AI-based technologies, increasing demand for AI tools in the medical field, growing focus on reducing the workload of radiologists, influx of large and complex datasets, growth in funding for AI-based start-ups, and growing number of cross-industry partnerships and collaborations.
Read More
15 Apr 2021
Microsoft Acquires Radiology Vendor Nuance to Deliver New Cloud and AI Capabilities Across Healthcare
Microsoft Corporation (Redmond, WA, USA) will acquire Nuance Communications, Inc. (Burlington, MA, USA) in an all-cash transaction valued at USD 19.7 billion to combine their solutions and expertise that will deliver new cloud and AI capabilities across healthcare and other industries.
Read More
14 Apr 2021
Zoll Medical Acquires CSA Systems Manufacturer Respicardia
 ZOLL Medical Corporation (Chelmsford, MA, USA), an Asahi Kasei company, has acquired Respicardia, Inc. (Minnetonka, MN, USA), a provider of novel implantable neurostimulators for the treatment of moderate to severe Central Sleep Apnea (CSA).
Read More
13 Apr 2021
DiaSorin to Acquire Luminex to Broaden Positioning in Molecular Diagnostics Space
DiaSorin S.p.A. (?Saluggia?, Italy) has announced that its Board of Directors has unanimously approved and signed a definitive merger agreement for DiaSorin to acquire Luminex Corporation (Austin, TX, USA) for approximately USD 1.8 billion.
Read More
13 Apr 2021
Philips Collaborates with AI Startup Ibex to Accelerate Adoption of AI-Powered Digital Pathology Solutions
Royal Philips (Amsterdam, The Netherlands) and Ibex Medical Analytics (Tel Aviv, Israel) have entered into a strategic collaboration to jointly promote their digital pathology and AI solutions to hospitals, health networks and pathology labs worldwide.
Read More
Copyright © 2000-2021 TradeMed.com. All rights reserved. | Terms And Conditions